Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 11 May 2022, 14:33 HKT/SGT
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead(TM) Programs at the TIDES USA 2022

Gaithersburg, MD, USA and Suzhou BioBay, China, May 11, 2022 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and a progress report on its GalAhead(TM) technologies and programs at the TIDES USA 2022 Conference. TIDES 2022 is taking place May 9-12, 2022 at the Hynes Convention Center in Boston.

Oral Presentation Details
-- Presentation Title: mxRNA(TM): Miniaturized RNAi Triggers Composed of Single Oligonucleotides
-- Presentation Segment: Oligonucleotide Discovery, Preclinical and Clinical
-- Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
-- Time/Date: 9:00am - 9:30am ET, Thursday, May 12, 2022.
-- Location: Hynes Convention Center, Room 102

Dr. Dmitry Samarsky, Sirnaomics Chief Technology Officer, will provide an oral presentation data demonstrating mxRNA efficacy in primary hepatocytes (in vitro) and in mice (in vivo). He will also present results of a 26-week study in non-human primates conducted with the candidate molecule for Sirnaomics' frontrunner GalAhead(TM) therapeutic program, targeting coagulation Factor XI, and report on progress made with other therapeutic programs based on the GalAhead(TM) platform.

For more information about Sirnaomics' presentation, visit the event website here.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at

Nigel Yip
Chief Financial Officer, China, Sirnaomics

Media (US):
Alexis Feinberg
Tel: +1 203 939 2225

Media (China):
Bunny Lee
Tel: +852 3150 6707

Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
nybl Joins World AI Show & Awards as The Official Artificial Intelligence Partner  
Sunday, May 22, 2022 9:07:00 AM
Straumann Malaysia, part of The Straumann Group, a Leading Implantology Company, Intends to Provide 3,000 Dental Implant Packages to the Ministry of Health Malaysia as part of MoU  
May 21, 2022 08:20 HKT/SGT
MC and Morgenrot Enter into Capital and Business Alliance  
Friday, May 20, 2022 7:19:00 PM
12th PropertyGuru Asia Property Awards (Singapore) search for the finest real estate as market sentiment improves  
May 20, 2022 19:15 HKT/SGT
PhilSec 2022 Set to Discuss Strategies to Strengthen Philippines' Cybersecurity  
May 20, 2022 16:35 HKT/SGT
TMT Offers Immersive Customer Experience with Latest Megastore in Pavilion Bukit Jalil  
May 20, 2022 16:00 HKT/SGT
ROOKIE Racing and TOM'S SPIRIT Announce Team Setups for Super Taikyu Series Fuji 24 Hours Race  
Friday, May 20, 2022 12:42:00 PM
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit  
May 20, 2022 11:10 HKT/SGT
MC and Kurashiki City Sign Regional Development Agreement  
Friday, May 20, 2022 9:55:00 AM
BDO announces winners of the BDO ESG Awards 2022  
Thursday, May 19, 2022 9:20:00 PM
More Press release >>
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: